Background Glucosamine and chondroitin sulfate are used to treat osteoarthritis. The
multicenter, double-blind, placebo- and celecoxib-controlled Glucosamine/chondroitin Arthritis …

Background Tofacitinib (CP-690,550) is a novel oral Janus kinase inhibitor that is being
investigated as a targeted immunomodulator and disease-modifying therapy for rheumatoid …

Background Tofacitinib (CP-690,550) is a novel oral Janus kinase inhibitor that is being
investigated for the treatment of rheumatoid arthritis. Methods In this 12-month, phase 3 trial, 717 …

Background. The optimal short-term, symptomatic therapy for osteoarthritis of the knee has
not been fully determined. Accordingly, we compared the efficacy of a nonsteroidal …

Mutating the CAACCCCAA sequence in the RNA component of telomerase causes the
synthesis in vivo of new telomere sequences corresponding to the mutated RNA sequence, …

Background Methotrexate is the most frequently used first-line antirheumatic drug. We report
the findings of a phase 3 study of monotherapy with tofacitinib, an oral Janus kinase inhibitor…

Objective The purpose of this 24‐month phase III study was to examine structural preservation
with tofacitinib in patients with rheumatoid arthritis (RA) with an inadequate response to …

Objective Osteoarthritis (OA) of the knee causes significant morbidity and current medical
treatment is limited to symptom relief, while therapies able to slow structural damage remain …

Background Knee osteoarthritis (OA) is a major cause of pain and functional limitation in
older adults, yet longer-term studies of medical treatment of OA are limited. Objective To …

Objective To confirm preclinical data suggesting that doxycycline can slow the progression
of osteoarthritis (OA). The primary outcome measure was joint space narrowing (JSN) in the …